摘要:
Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Patent Claim (1), are suitable as antidiabetics.
摘要:
Novel compounds of the formula I (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R, Q, W, X and Z have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.
摘要:
Novel compounds of the formula I, in which X, Y, R, R′, R1, R1′, R1″, R2, R2′, R2″, R3, R3′, R4, R4′ and n have the meanings indicated in Patent Claim 1, are suitable as antidiabetics
摘要:
Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Patent Claim (1), are suitable as antidiabetics.
摘要:
Novel compounds of the formula I (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R, Q, W, X and Z have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.
摘要:
Novel compounds of the formula (I), in which X, Y, R, R1, R1, R1′, R2, R2′, R3, R4, R4′, R5 and n have the meanings indicated in patent claim 1, are suitable as antidiabetics.
摘要:
Novel compounds of the formula (I), in which X, Y, R, R1, R1, R1′, R2, R2′, R3, R4, R4′, R5 and n have the meanings indicated in patent claim 1, are suitable as antidiabetics.
摘要:
Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5, R6 and X7 have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.
摘要:
Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5, R6 and X7 have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.
摘要:
Novel acyl hydrazides of the formula (I), in which R1-R9 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type.